bioRxiv · 10.1101/2020.10.05.327122
Lysophosphatidic acid (LPA)-antibody (504B3)validation by free-solution assay and interferometry identifies off-target binding
Abstract
Antibody specificity and sensitivity is required in basic and clinical research for ensuring scientific rigor and reproducibility, while off-target cross-reactivity could generate erroneous conclusions. Lysophosphatidic acid (LPA) is a bioactive lipid being targeted clinically by antibody strategies. Here, we reexamined binding properties of a commercially available monoclonal antibody (504B3) reported as specific for LPA using a free-solution assay measured in a compensated interferometric reader. The antibody showed comparable binding affinities to LPA and non-LPA lipids including phosphatidic acid (PA) and lysophosphatidylcholine (LPC). These results may alter conclusions drawn from current and past basic and clinical studies employing anti-LPA antibodies.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ray, M., Kihara, Y., Bornhop, D. J., Chun, J.. 2020-10-05. Lysophosphatidic acid (LPA)-antibody (504B3)validation by free-solution assay and interferometry identifies off-target binding. https://doi.org/10.1101/2020.10.05.327122
Cite the original work for its findings. Save a collection to share your selection of sources.